This article was originally published in The Tan Sheet
Dr. Reddy's Labs has filed ANDA for fexofenadine 30 mg, 60 mg and 180 mg, equivalent to Aventis' Allegra, firm says March 25. Aventis subsequently filed lawsuit in New Jersey federal court alleging patent infringement on six Orange Book patents, Dr. Reddy's notes. Firm will likely switch products in future; Hyderabad, India-based Dr. Reddy's recently sealed distribution deal with Leiner to expand foothold in U.S. OTC drug market (1"The Tan Sheet" March 3, 2003, p. 3)...
You may also be interested in...
Dr. Reddy's Laboratories' foothold in the U.S. OTC drug market appears ready for expansion after the firm signed an exclusive 15-year OTC product development and marketing agreement with Leiner Health Products
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.